<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">50519</article-id><article-id pub-id-type="doi">10.22363/2313-0245-2025-30-2-248-255</article-id><article-id pub-id-type="edn">GUOESJ</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MEDICAL GENETICS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МЕДИЦИНСКАЯ ГЕНЕТИКА</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association of BAP1 polymorphisms with development of uveal melanoma</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциация полиморфизмов гена BAP1 с развитием увеальной меланомы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2427-5589</contrib-id><contrib-id contrib-id-type="spin">5766-1940</contrib-id><name-alternatives><name xml:lang="en"><surname>Mukhana</surname><given-names>Lujin</given-names></name><name xml:lang="ru"><surname>Мухана</surname><given-names>Л.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4256-5785</contrib-id><contrib-id contrib-id-type="spin">8959-9778</contrib-id><name-alternatives><name xml:lang="en"><surname>Ahmed</surname><given-names>Abdulbary Amin M.</given-names></name><name xml:lang="ru"><surname>Ахмед</surname><given-names>А. А. М.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7720-0727</contrib-id><contrib-id contrib-id-type="spin">6451-3241</contrib-id><name-alternatives><name xml:lang="en"><surname>Gigani</surname><given-names>Olga O.</given-names></name><name xml:lang="ru"><surname>Гигани</surname><given-names>О. О.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8591-428X</contrib-id><contrib-id contrib-id-type="spin">4783-9193</contrib-id><name-alternatives><name xml:lang="en"><surname>Saakyan</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>Саакян</surname><given-names>С. В.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9475-3545</contrib-id><contrib-id contrib-id-type="spin">6476-4740</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsygankov Alexander</surname><given-names>Yu. Yu.</given-names></name><name xml:lang="ru"><surname>Цыганков</surname><given-names>А. Ю.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7290-1196</contrib-id><contrib-id contrib-id-type="spin">2590-1013</contrib-id><name-alternatives><name xml:lang="en"><surname>Azova</surname><given-names>Madina M.</given-names></name><name xml:lang="ru"><surname>Азова</surname><given-names>М. М.</given-names></name></name-alternatives><email>gigani_oo@pfur.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">RUDN University</institution></aff><aff><institution xml:lang="ru">Российский университет дружбы народов имени Патриса Лумумбы</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Helmholtz National Medical Research Center of Eye Diseases</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Russian University of Medicine</institution></aff><aff><institution xml:lang="ru">Российский университет медицины</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-06-07" publication-format="electronic"><day>07</day><month>06</month><year>2026</year></pub-date><volume>30</volume><issue>2</issue><issue-title xml:lang="en">PHISIOLOGY. EXPERIMENTAL PHYSIOLOGY</issue-title><issue-title xml:lang="ru">ФИЗИОЛОГИЯ. ЭКСПЕРИМЕНТАЛЬНАЯ ФИЗИОЛОГИЯ</issue-title><fpage>248</fpage><lpage>255</lpage><history><date date-type="received" iso-8601-date="2026-06-07"><day>07</day><month>06</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Mukhana L., Ahmed A.A., Gigani O.O., Saakyan S.V., Tsygankov Alexander Y.Y., Azova M.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Мухана Л., Ахмед А.А., Гигани О.О., Саакян С.В., Цыганков А.Ю., Азова М.М.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Mukhana L., Ahmed A.A., Gigani O.O., Saakyan S.V., Tsygankov Alexander Y.Y., Azova M.M.</copyright-holder><copyright-holder xml:lang="ru">Мухана Л., Ахмед А.А., Гигани О.О., Саакян С.В., Цыганков А.Ю., Азова М.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/50519">https://journals.rudn.ru/medicine/article/view/50519</self-uri><abstract xml:lang="en"><p>Relevance. Uveal melanoma is a rare form of cancer that originates in the eye, most frequently arises in the choroid (90%). BAP1 is a tumor suppressor gene, mutations in this gene were found in 40-84% of primary UM. Given many investigators have proven the association of mutations in the BAP1 gene with UM. Aim: our study aims to figure out UM associated polymorphisms by sequencing DNA in exon 10, exon 11, exon 15, exon 16, and exon 17 as well as to assess the role of BRCA1 mutations in risk of UM development. Materials and Methods. A total of 95 individuals recruited in the study, out of them 42 as a patient group, 23 as a risk group, and 30 as a control group. The target regions of BAP1 gene amplified by PCR were sequenced by Sanger method and BRCA1 was genotyped by real-time PCR using commercially produced kits. Results and Discussion. This study did not demonstrate presence of any polymorphisms in the sequenced regions of the BAP1 gene or the genotyped specific BRCA1 sites that are correlated with an increased risk of uveal melanoma development. Our findings do not deny the published strong association between BAP1 inactivating mutations and the UM disease. This study’s findings instead propose that within this targeted population, the molecular mechanisms for BAP1 loss-function may include aberrations other than changes in the examined exons. Conclusion. Consequently, we recommend future research that includes sequencing the entire BAP1 gene in larger sized samples and studying of other candidate genes.</p></abstract><trans-abstract xml:lang="ru"><p>Актуальность. Увеальная меланома (УМ) представляет собой редкую форму онкопатологии, которая развивается в глазу и наиболее часто возникает в хориоидее (90 %). BAP1 является геном-супрессором опухолей; мутации в этом гене обнаруживаются в 40-84 % случаев первичной УМ. Учитывая, что многие исследователи показали связь мутаций в гене BAP1 с УМ. Цель: целью нашей работы стало выявить ассоциированные с УМ полиморфные варианты в экзонах 10, 11, 15, 16 и 17, а также оценить роль мутаций гена BRCA1 в развитии УМ. Материалы и методы. Всего в исследовании приняли участие 95 человек, включая 42 пациента с УМ, 23 пациента из группы риска и 30 добровольцев контрольной группы. Целевые участки гена BAP1, амплифицированные с помощью ПЦР, были секвенированы методом Сэнгера; генотипирование по гену BRCA1 проводилось методом ПЦР в реальном времени. Результаты и обсуждение. Настоящее исследование не выявило полиморфных вариантов в секвенированных последовательностях гена BAP1 и мутаций гена BRCA1, которые были бы ассоциированы с повышенным риском развития УМ. Наши результаты не опровергают литературные данные о связи между инактивирующими мутациями BAP1 и увеальной меланомой, но позволяют предполагать, что молекулярные механизмы потери функции BAP1 могут включать нарушения за пределами исследованных экзонов. Выводы. Таким образом, целесообразны дальнейшие исследования с секвенированием всего гена BAP1 в выборках большего объёма и изучением других кандидатных генов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>uveal melanoma</kwd><kwd>BAP1</kwd><kwd>BRCA1</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>увеальная меланома</kwd><kwd>BAP1</kwd><kwd>BRCA1</kwd></kwd-group><funding-group/></article-meta><fn-group/></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Liu X, Liu C, Shang Y, Yang L, Tan F, Lv Y. Prognostic Factors and Nomograms for Overall and Cancer-­Specific Survival of Patients with Uveal Melanoma without Metastases: A SEER Analysis of 4119 Cases. Journal Ophthalmology. 2022:1874336. doi:10.1155/2022/1874336</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Akin-­Bali DF. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1, SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma. Ophthalmic Genetics. 2021;42(6):732–743. doi:10.1080/13816810.2021.1961280</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Nanda H, Barrett MT. Investigation of unknown causes of uveal melanoma uncovers seven recurrent genetic mutations. Journal of Emerging Investigators. 2022;5. doi.org/10.59720/21–203</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Dono M, Angelini G, Cecconi M, Amaro A, Esposito A, Mirisola V, et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. British Journal of Cancer. 2014;110(4):1058–1065. doi:10.1038/bjc.2013.804</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chalada M, Ramlogan-­Steel CA, Dhungel BP, Christopher JL, Jason CS. The Impact of Ultraviolet Radiation on the Aetiology and Development of Uveal Melanoma. Cancers (Basel). 2021;13(7):1700. doi:10.3390/cancers13071700</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Pierce ES, Jindal C, Choi YM, Efird JT. The evidence for Mycobacterium avium subspecies paratuberculosis (MAP) as a cause of nonsolar uveal melanoma: a narrative review. Translational Cancer Research. 2023;12(2):398–412. doi:10.21037/tcr-22-2540</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Jumaniyazova ED, Sentyabreva AV, Kosyreva AM, Lokhonina AV. Molecular genetic signatures of head and neck squamous cell carcinoma and their changes induced by proton irradiation. RUDN Journal of Medicine. 2024;28(4):413–426. doi:10.22363/2313-0245-2024-28-4-413-426</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Banimohammad M, Khalafi P, Gholamin D, Bangaleh Z, Akhtar N, Solomon AD, et al. Exploring recent advances in signaling pathways and hallmarks of uveal melanoma: a comprehensive review. Exploration of Targeted Anti-­Ttumor Therapy. 2025;6:1002306. doi:10.37349/etat.2025.1002306</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Van Essen TH, van Pelt SI, Versluis M, Versluis M, Bronkhorst IHG, van Duinen SG, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. British Journal of Ophthalmology. 2014;98(12):1738–1743. doi:10.1136/bjophthalmol-2014-305047</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Johansson PA, Palmer JM, McGrath L, Warrier S, Hamilton HR, Beckman T, et al. Germline Variants in Patients Affected by Both Uveal and Cutaneous Melanoma. Pigment Cell Melanoma Research. 2025;38(1): e13199. doi:10.1111/pcmr.13199</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kwon J, Lee D, Lee SA. BAP1 as a guardian of genome stability: implications in human cancer. Experimental &amp; molecular medicine. 2023;55(4):745–754. doi:10.1038/s12276-023-00979-1</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Masclef L, Ahmed O, Estavoyer B, Larrivée B, Labrecque N, Nijnik A, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death and Differentiation. 2021;28(2):606–625. doi:10.1038/s41418-020-00709-4</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Niersch J, Vega-­Rubín-de-­Celis S, Bazarna A, et al. A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosis. iScience. 2021;24(3):102173. doi:10.1016/j.isci.2021.102173</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Szegedi K, Szabó Z, Kállai J, Király J, Szabó E, Bereczky Z, Juhász É, Dezső B, Szász C, Zsebik B, et al. Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors. Journal of Clinical Medicine. 2023; 12(13):4538. https://doi.org/10.3390/jcm12134538</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Goldstein AM. Germline BAP1 mutations and tumor susceptibility. Nature genetics. 2011;43(10):925–926. doi:10.1038/ng.956</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Peng H, Prokop J, Karar J, Park K, Caoet L, Harbour JW. Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer research. 2018;78(5):1200–1213. doi: 10.1158/0008-5472.CAN-17-2876</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Louie BH, Kurzrock R. BAP1: Not just a BRCA1‑associated protein. Cancer treatment reviews. 2020;90:102091. doi: 10.1016/j.ctrv.2020.102091</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Sahtoe DD, van Dijk WJ, Ekkebus R, Ovaa H, Sixma TK. BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nature Сommunications. 2016; 7:10292. doi:10.1038/ncomms10292</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Daou S, Barbour H, Ahmed O, Masclef L, Baril С, Nkwe NS. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1. Nature Сommunications. 2018;9(1):4385. doi:10.1038/s41467-018-06854-2</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ewens KG, Lalonde E, Richards-­Yutz J, Shields CL, Ganguly A. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma. BMC Cancer. 2018;18(1):1172. doi:10.1186/s12885-018-5079-x</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1‑associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer research. 2009;69(1):111–119. doi: 10.1158/0008-5472.CAN-08-3355</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rodrigues M, Ait Rais K, Salviat F, Algret N, Simaga F, Barnhill R. Association of Partial Chromosome 3 Deletion in Uveal Melanomas with Metastasis-­Free Survival. JAMA Ophthalmology. 2020;138(2):182–188. doi:10.1001/jamaophthalmol.2019.5403</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lee SA, Lee D, Kang M, Kim S, Kwon SJ, Lee HS. BAP1 promotes the repair of UV-induced DNA damage via PARP1‑mediated recruitment to damage sites and control of activity and stability. Cell Death and Differentiation. 2022;29(12):2381–2398. doi:10.1038/s41418-022-01024-w</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mukhana L, Aissa AA, Ahmed AAM, Saakyan SV, Tsygankov AYu, et al. Association of BARD1 and BRIP1 Gene Polymorphisms with the Risk of Uveal Melanoma. Bulletin of Experimental Biology and Medicine. 2023;175(3):399–403. doi:10.1007/s10517-023-05875-2</mixed-citation></ref></ref-list></back></article>
